LabCorp Announces Acquisition of Bode Technology

Acquisition expands LabCorp’s forensic DNA testing and relationship analysis capabilities BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 5, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of Bode Technology Group, Inc.

LabCorp Completes Acquisition of LIPOSCIENCE

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 21, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014 . At a special meeting held on November 20, 2014 , LIPOSCIENCE’s

LabCorp to Acquire Covance for Approximately $5.6 Billion, Creating World’s Leading Healthcare Diagnostics Company

Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share Combination creates comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics development and commercialization Transaction expected to be

Laboratory Corporation of America® Holdings Announces 2014 Third Quarter Results and Increases 2014 EPS Guidance

Strong volume growth drives sales of $1.55 billion Diluted EPS of $1.59 ; Adjusted EPS of $1.80 Operating Cash Flow of $176 million ; Free Cash Flow of $123 million 2014 Adjusted EPS guidance raised to $6.70 - $6.80 BURLINGTON, N.C. --(BUSINESS WIRE)--Oct.

LabCorp Introduces HIV-1 Next Generation Sequencing Assay to Support Drug Regimen Changes in HIV Suppressed Patients

GenoSure Archive SM is the first genotypic drug resistance assay to interrogate HIV-1 DNA BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 20, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) and Monogram Biosciences, Inc. , part of the LabCorp Specialty Testing Group , today

LabCorp’s Acquisition of LipoScience Clears Antitrust Approval

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 15, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces Agreement to Acquire LipoScience

Acquisition Price of $5.25 Per Share in All Cash Transaction NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 25, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) and LipoScience, Inc.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of September 12, 2014 to March 11, 2015 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp’s Enlighten Health Launches Innovative Genomics Initiative

Enlighten Health Genomics Aims to Make Genetic Profiles a Routine Part of Clinical Decisions BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 4, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ; NYSE: LH) announced today the launch of Enlighten Health Genomics, a new business that builds on